炔諾酮

炔諾酮
臨床資料
商品名（英語：Drug nomenclature）	Alone: Aygestin, Camila, Heather, Micronor, Primolut N, others; With EE: Lo Loestrin, Loestrin, Microgestin, Modicon, Norinyl, Ortho-Novum, others; With E2: Activella, Activelle, Estalis, Kliogest, Necon, Novofem, Trisequens, others
其他名稱	NET; Norethindrone; NSC-9564; LG-202; Ethinylnortestosterone; Norpregneninolone; Anhydrohydroxy-norprogesterone; Ethinylestrenolone; 17α-Ethynyl-19-nortestosterone; 17α-Ethynylestra-4-en-17β-ol-3-one; 17α-Hydroxy-19-norpregn-4-en-20-yn-3-one
AHFS/Drugs.com	國際藥品名稱
MedlinePlus	a604034
給藥途徑	By mouth, intramuscular injection (as NETE)
藥物類別（英語：Drug class）	Progestin; Progestogen
ATC碼	G03AC01 (WHO) G03DC02;
藥物動力學數據
生物利用度	47–73% (mean 64%)
血漿蛋白結合率	97%:; Albumin: 61%;; SHBG: 36%
藥物代謝	Mainly CYP3A4 (liver); also 5α-/5β-reductase, 3α-/3β-HSD, and aromatase
生物半衰期	5.2–12.8 hours (mean 8.0 hours)
識別資訊
	IUPAC命名法 (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one; ;
CAS號	68-22-4
PubChem CID	6230;
IUPHAR/BPS	2880;
DrugBank	DB00717 ;
ChemSpider	5994 ;
UNII	T18F433X4S;
KEGG	D00182 ;
ChEBI	CHEBI:7627 ;
ChEMBL	ChEMBL1162 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID9023380 ;
ECHA InfoCard	100.000.619
化學資訊
化學式	C20H26O2
摩爾質量	298.419 g/mol
3D模型（JSmol（英語：JSmol））	交互式圖像;
熔點	203至204 °C（397至399 °F）
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34;
	InChI InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1 ; Key:VIKNJXKGJWUCNN-XGXHKTLJSA-N ;

炔諾酮（英語：Norethisterone 或英語：norethindrone）是一種黃體製劑藥物，用做口服避孕藥和激素替代療法藥物以及治療一些婦科疾病^[4]。

另見

醋酸炔諾酮，炔諾酮的乙酸酯

參考文獻

^ ^1.0 ^1.1 Stanczyk, Frank Z. Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception (PDF). Reviews in Endocrine and Metabolic Disorders. Sep 2002, 3 (3): 211–224. ISSN 1389-9155. PMID 12215716. doi:10.1023/A:1020072325818.
^ Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. August 1996, 54 (2): 59–69. PMID 8842581. doi:10.1016/0010-7824(96)00136-9.
^ Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J. Steroid Biochem. Mol. Biol. 2008, 110 (1–2): 56–66. PMID 18356043. doi:10.1016/j.jsbmb.2007.09.025.
^ Kathryn Rhodes Alden; Deitra Leonard Lowdermilk; Mary Catherine Cashion; Shannon E. Perry. Maternity and Women's Health Care - E-Book. Elsevier Health Sciences. 27 December 2013: 135– [2019-06-30]. ISBN 978-0-323-29368-6. （原始內容存檔於2020-01-04）.

[pmid12215716-1] 1.0 ^1.1 Stanczyk, Frank Z. Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception (PDF). Reviews in Endocrine and Metabolic Disorders. Sep 2002, 3 (3): 211–224. ISSN 1389-9155. PMID 12215716. doi:10.1023/A:1020072325818.

[pmid8842581-2] Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. August 1996, 54 (2): 59–69. PMID 8842581. doi:10.1016/0010-7824(96)00136-9.

[pmid18356043-3] Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J. Steroid Biochem. Mol. Biol. 2008, 110 (1–2): 56–66. PMID 18356043. doi:10.1016/j.jsbmb.2007.09.025.

[AldenLowdermilk2013-4] Kathryn Rhodes Alden; Deitra Leonard Lowdermilk; Mary Catherine Cashion; Shannon E. Perry. Maternity and Women's Health Care - E-Book. Elsevier Health Sciences. 27 December 2013: 135– [2019-06-30]. ISBN 978-0-323-29368-6. （原始內容存檔於2020-01-04）.

[1]

[2]

[3]

[4]